Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (231-240 of 502) with videos related to

Pageof 51
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.
NPJ Precision Oncology|September 1, 2022
Spatially variant immune infiltration scoring in human cancer tissuesMayar Allam, Thomas Hu, Jeongjin Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 16, 2016
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trialsS S Ramalingam, K O'Byrne, M Boyer, et al.
Oncogene|October 18, 2011
Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivoI Ramachandran, E Thavathiru, S Ramalingam, et al.
Cancer|September 30, 2017
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literatureRathi N Pillai, Madhusmita Behera, Taofeek K Owonikoko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2014
Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysisConor E Steuer, Madhusmita Behera, Sungjin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 8, 2018
Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung CancerSteven E Schild, Wen Fan, Thomas E Stinchcombe, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 24, 2024
Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung CancerZhen Chen, Karin A Vallega, Vijay K Boda, et al.
Indian Journal of Medical Microbiology|July 24, 2007
The immunological and virological response in human immunodeficiency virus type-1 (HIV-1) infected Indian individuals on HAART therapy: a one-year follow up studyR Kannangai, S Ramalingam, T S Vijayakumar, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world studyHossein Borghaei, Xerxes Pundole, Laura Sangaré, et al.
Pageof 51

Showing results (231-240 of 502) with videos related to

Sort By:
Pageof 51
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.
NPJ Precision Oncology|September 1, 2022
Spatially variant immune infiltration scoring in human cancer tissuesMayar Allam, Thomas Hu, Jeongjin Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 16, 2016
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trialsS S Ramalingam, K O'Byrne, M Boyer, et al.
Oncogene|October 18, 2011
Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivoI Ramachandran, E Thavathiru, S Ramalingam, et al.
Cancer|September 30, 2017
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literatureRathi N Pillai, Madhusmita Behera, Taofeek K Owonikoko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2014
Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysisConor E Steuer, Madhusmita Behera, Sungjin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 8, 2018
Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung CancerSteven E Schild, Wen Fan, Thomas E Stinchcombe, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 24, 2024
Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung CancerZhen Chen, Karin A Vallega, Vijay K Boda, et al.
Indian Journal of Medical Microbiology|July 24, 2007
The immunological and virological response in human immunodeficiency virus type-1 (HIV-1) infected Indian individuals on HAART therapy: a one-year follow up studyR Kannangai, S Ramalingam, T S Vijayakumar, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world studyHossein Borghaei, Xerxes Pundole, Laura Sangaré, et al.
Pageof 51